Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333056 | 0.91 | EGFR (0.41) | JAK3BTKMETALKEGFR | |
| SCHEMBL4364555 | 0.91 | JAK3 (0.43) | JAK3BTKEGFRMAPTJAK2 | |
| SCHEMBL1025084 | 0.87 | JAK3 (0.42) | JAK3BTKEGFRMAPTJAK2 | |
| SCHEMBL13623085 | 0.86 | SYK (0.45) | JAK3BTKMETALKEGFR | |
| SCHEMBL13623083 | 0.85 | BCL6 (0.44) | JAK3METALKEGFRJAK2 | |
| SCHEMBL1025086 | 0.84 | BCL6 (0.38) | JAK3BTKMETALKEGFR | |
| Trifluoroacetic Acid SCHEMBL1026827 | 0.84 | CTSC (0.41) | METALK | |
| SCHEMBL4335022 | 0.84 | BTK (0.42) | JAK3BTKEGFR | |
| SCHEMBL13670005 | 0.84 | CTSC (0.37) | JAK3EGFRJAK2JAK1 | |
| SCHEMBL4334815 | 0.84 | EGFR (0.42) | BTKMETALKEGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK3 4/4885BTK 20/4885MET 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.